Edward Brennan, Jr., M.D., FACS to Lead FSD Pharma BioSciences Division

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"\n\n\n\nEdward Brennan, Jr., M.D., FACS to Lead FSD Pharma BioSciences Division\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, May 28, 2019\n\n\n\nTORONTO, May 28, 2019 /CNW/ - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (\"FSD\" or the \"Company\"), today announced the appointment of pharmaceutical industry leader, Edward J. Brennan, Jr., M.D., FACS, as President of its biosciences division. Dr. Brennan has more than 25 years' experience in leadership roles at major pharmaceutical companies and clinical research organizations.\n\n \n \n\n \n\"Ed is an accomplished biopharmaceutical executive with a proven track record in FDA submissions and drug development,\" said Dr. Raza Bokhari, FSD Executive Co-Chairman & Chief Executive Officer. \"We aim to capitalize on his expert guidance as FSD builds on our recently announced acquisition of Prismic Pharmaceuticals and continues to execute on our strategy to identify and acquire cannabinoid-based pharmaceutical R&D companies focused on FDA approved clinical trials\". \n\"Leading FSD's Biosciences Division is a very exciting opportunity for me. The company's paradigm shift to unlock the promise of the synthetic cannabinoid molecule is bold but timely\" said Dr. Brennan. \"I look forward to leading the company's team in realizing our vision to advance R&D of FDA-approved synthetic cannabinoids and other synergistic molecules.\"\nDr. Brennan has extensive experience in all phases of clinical development across multiple therapeutic areas. As a Medical Director with Wyeth-Ayerst Research and GlaxoSmithKline, he led teams through ten IND applications and advanced multiple compounds from pre-candidate selection (proof of concept) through clinical trial management and approval. At GSK, he was also responsible for coordinating all clinical activities for external partners within its Center of Excellence in External Drug Discovery. He next ...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B